Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Crawford under investigation

Executive Summary

Former FDA Commissioner Lester Crawford is under a criminal investigation concerning financial disclosures and potentially false statements before Congress, according to statements made by his lawyer during a court hearing for the civil case brought by the Center for Reproductive Rights over the agency's handling of Barr's Plan B over-the-counter switch application. Crawford's attorney requested a deposition be delayed due to potential overlap with an ongoing grand jury investigation. Failing to disclose certain financial conflicts is rumored to be one reason for Crawford's abrupt departure from the agency in September (1"The Pink Sheet" Sept. 26, 2005, p. 3)...

You may also be interested in...



Commissioner Von Eschenbach: NCI Director Named Acting Head Of FDA

National Cancer Institute Director Andrew von Eschenbach, MD, brings extensive scientific expertise and experience working with Congress as the head of a high-profile federal agency to the role of FDA commissioner

Swiss Health Providers Turn Heat On Federal Council Fearing 12% Loss Of Medtech On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.

New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster

China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.

UsernamePublicRestriction

Register

OM017315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel